MEET THE TEAM
Pacific Bridge NY is led by an experienced investment, clinical, and operating team, supported by an advisory council and clinical experts from leading academic and biopharmaceutical institutions.
Marc S. Appel
Managing Partner
Marc is the founder and Managing Partner of Pacific Bridge NY. Previously, he founded the drug investment and development platform Orange Grove Bio and served as its CEO where he helped launch and lead multiple portfolio companies, including IpiNovyx Bio, Asalyxa Bio, and Allonix Therapeutics.
Before founding Pacific Bridge NY and Orange Grove Bio, Marc was a healthcare investor at Marathon Asset Management, where he invested across the capital structure and helped develop a structured healthcare and royalty investing strategy. He began his career at McKinsey & Company.
Marc is also an active advisor to university innovation programs, including the Frankel Fund at the University of Michigan, Yale’s Blavatnik Program, Cornell University’s tech transfer office, and the Dartmouth Innovations Accelerator for Cancer. He frequently speaks at industry conferences and academic institutions and is the co-author of a Harvard Business School case on Imprimis Pharmaceuticals.
Throughout his career, Marc has founded and invested in many biotech companies and negotiated, structured, and led numerous partnerships with large pharmaceutical companies and has served on the boards of biotechs across stages, therapeutic areas, and modalities.
He holds a B.A. from Yale University, a J.D. from Harvard Law School, and an M.B.A. from Harvard Business School. He is a member of the New York Bar.
Joe Walker
Partner
Joe is a Partner of Pacific Bridge NY. He brings more than 25 years of executive leadership experience across global pharmaceutical and biotechnology companies, with deep expertise in early drug development, translational strategy, and cross-functional program leadership.
Previously, Joe held senior leadership roles at Bristol Myers Squibb, Celgene, and Daiichi Sankyo, where he led programs from candidate nomination through IND filing and clinical proof-of-concept. At BMS, he served as Vice President and Senior Global Program Leader for Neuroscience, with full accountability for the development of the neuroscience portfolio. Across his career, he has filed more than ten INDs and helped build foundational R&D capabilities from the ground up.
Before joining BMS, Joe was Executive Director of Global Project Leadership at Celgene, where he led large, global, matrixed development teams and was accountable to executive governance for overall program vision, development strategy, and execution. He served as Global Program Lead on multiple oncology assets, including bispecific antibodies, monoclonal antibodies, targeted protein degraders, and small-molecule inhibitors.
Earlier in his career at Daiichi Sankyo, Joe held leadership roles in Companion Diagnostics, Pharmacogenomics, and Clinical Pharmacology, where he designed and executed innovative early clinical development strategies from first-in-human through proof-of-concept. He has deep technical expertise in clinical pharmacology, biomarker strategy, pharmacogenomics, and personalized medicine, with therapeutic experience spanning neuroscience, neurodegeneration, oncology, thrombosis, and diabetes.
Joe is the author or co-author of multiple peer-reviewed publications in leading medical journals, including The Lancet and The New England Journal of Medicine, and is the recipient of the 2010 McKeen Cattell Memorial Award for Outstanding Manuscript in the Journal of Clinical Pharmacology. He is widely recognized as a leader of leaders with extensive experience guiding complex programs through critical development inflection points.
He holds a PharmD from the University of Tennessee and completed postgraduate training including a residency and a post-doctoral fellowship in pharmacogenomics.
Min (Winnie) Wang
Partner
Winnie is a Partner of Pacific Bridge NY. She brings over 20 years of experience in pharmaceutical and life sciences business development, with deep expertise in partnering, licensing, and alliance management, and a particular focus on facilitating complex cross-border transactions..
Previously, Winnie held senior business development and alliance leadership roles at Roche, Sanofi, Fosun Pharma, and GeneScience Pharmaceuticals. Most recently, she served as Partnering and Alliance Management Director at Roche, where she led international partnering initiatives and alliance management efforts. At Sanofi, she was Asia Alliance Director for Business Development and Licensing, responsible for regional partnering strategy and execution across multiple therapeutic areas.
Before joining Sanofi in her alliance leadership role, Winnie spent more than six years at Sanofi in External Innovation and Business Development, where she sourced, structured, negotiated, and executed licensing and collaboration agreements with global biotech and pharmaceutical partners. She played a key role in advancing Sanofi’s external innovation strategy across Asia and strengthening long-term strategic partnerships.
Earlier in her career, Winnie served as Business Development Director at Fosun Pharma and Head of Business Development at GeneScience Pharmaceuticals, where she led corporate strategy, international business development, and cross-border transaction execution. Across her roles, she has built a strong track record of identifying high-quality assets and partners and translating strategic priorities into executed transactions.
Throughout her career, Winnie has been recognized for her ability to bridge global organizations, cultures, and deal structures, and for her leadership in driving successful international collaborations within the pharmaceutical and life sciences ecosystem.
Taylor Negrete
Head of Investor Relations & Operations
Taylor is the Head of Investor Relations & Operations at Pacific Bridge NY. She leads the firm’s investor relations, strategic communications, and operational functions, and plays a central role in supporting the firm’s growth, investment activities, and long-term strategy.
Earlier in her career, Taylor held operations, executive management, and client-facing roles across startup and technology-driven organizations, including Linear Technology, where she gained experience in international business and stakeholder engagement. Throughout her career, she has been recognized for her ability to build trusted relationships, bring structure to complex environments, and operate as a strategic partner to senior leadership.
She holds a B.S. in Public Relations from San José State University.
Jordan Schultz
Investment Associate
Jordan is an Investment Associate at Pacific Bridge NY. She focuses on scientific diligence, transaction execution, and deal negotiation across the firm’s biotechnology investments. She works closely with founders, management teams, and scientific advisors to evaluate clinical-stage therapeutic opportunities, assess commercial potential, and support the acquisition and development of innovative global assets for the U.S. market.
Prior to joining Pacific Bridge NY, Jordan held roles in business development, technology transfer, and startup support at Yale University, the University of Georgia, and Clemson University. In these positions, she led and supported intellectual property licensing transactions, negotiated commercial agreements, managed technology portfolios, and worked closely with academic founders and early-stage companies to advance the commercialization of novel life sciences innovations. Her experience spans scientific research, intellectual property strategy, and business development, providing a strong foundation for evaluating emerging therapeutic platforms and development-stage assets.
Jordan holds a Ph.D. in Biochemistry from Clemson University.
Cecilia Ren
Executive Assistant
Cecilia is a Multilingual Executive Assistant at Pacific Bridge NY. She provides administrative support to the team, assists with communications and scheduling, and supports the firm’s day-to-day operations.
Prior to joining Pacific Bridge NY, Cecilia held executive support, operations, and translation roles across multinational organizations including Oatly, SAP, Borgward Automobile Group, and the Canadian Olympic Committee. Throughout her career, she has supported senior executives in fast-paced international environments and developed strong organizational, communication, and cross-cultural coordination skills.
Fluent in Mandarin, English, and Japanese, Cecilia holds a Bachelor’s degree from Seneca College and a Bachelor’s degree in Japanese Literature from Heilongjiang University.
Tony Chao
Senior Advisor
Tony is a Senior Advisor at Pacific Bridge NY. He brings more than two decades of experience building cross-border relationships and fostering international collaboration across business, government, and academia. He supports the firm’s engagement in China and broader Asia, helping strengthen strategic relationships and identify opportunities for cross-border partnership and collaboration.
Throughout his career, Tony has held senior roles supporting U.K.–China enterprises and has participated in major international forums, including the China–EU and China–U.K. Summits. He has developed extensive networks across government, industry, and academic institutions through his work with the Western Returned Scholars Association (WRSA) and a range of cultural and economic exchange initiatives.
As Chief China Representative for the Buffett Shareholders Meeting – China–U.S. Investment Forum, Tony has convened lawmakers, Fortune 500 executives, investors, and global thought leaders during pivotal moments in U.S.–China relations. He is widely recognized for his ability to connect stakeholders across sectors and advance high-impact international cooperation.
Ho Cho
Venture Partner
Ho is a Venture Partner at Pacific Bridge NY. Dr. Cho is a biotechnology executive and protein medicinal chemist with more than two decades of experience leading research organizations, building innovative therapeutics companies, and advancing biologics from discovery through development. He supports the firm’s investment activities through scientific diligence, technical de-risking, and strategic guidance across emerging therapeutic platforms and biotechnology opportunities.
Most recently, Dr. Cho served as Executive Vice President, Chief Scientific Officer, and Head of Research and Early Development at Samsung Bioepis, where he helped expand the company’s focus from biosimilars to novel biologics and led the advancement of its first antibody-drug conjugate (ADC) programs. Previously, he held senior leadership positions at Bristol Myers Squibb and Celgene, overseeing biotherapeutics organizations and integrating external collaborations with internal research teams to deliver development candidates across multiple therapeutic areas.
Earlier in his career, Dr. Cho served as Chief Technology Officer at Ambrx, where he helped establish the company as a leader in protein engineering and site-specific bioconjugation technologies through the development of novel ADC platforms and strategic industry partnerships. He has also served on the boards of Protomer Technologies, Boundless Bio, and AMC Sciences.
Dr. Cho holds a Ph.D. in Chemistry from the University of California, Berkeley.
Peter Worland
Senior Advisor
Peter is a Senior Advisor at Pacific Bridge NY. He brings more than three decades of pharmaceutical and biotechnology R&D leadership experience to Pacific Bridge NY. He supports the firm’s investment activities through scientific diligence, portfolio strategy, and the evaluation of emerging therapeutic technologies and development opportunities.
Most recently, Peter served as Senior Vice President of Integrative Sciences at Bristol Myers Squibb, where he led global collaboration efforts and helped establish more than 30 strategic partnerships across academia and industry to expand research capabilities and therapeutic innovation. Previously, he held senior leadership positions at Celgene, overseeing Experimental Therapeutics and Integrative Research Development, where he played a key role in advancing research programs and strengthening external innovation initiatives.
Earlier in his career, Peter held scientific and leadership roles at Pharmacia, Mitotix, and Millennium Pharmaceuticals, contributing to the advancement of multiple small molecule and biologic therapies into clinical development.
Peter earned his Ph.D. from the University of Melbourne and conducted research at the National Cancer Institute before entering industry.
Jarrat Jordan
Venture Advisor
Jarrat is a Venture Advisor to Pacific Bridge NY. He brings over 20 years of experience in immunology research and drug discovery across large pharmaceutical companies and innovative biotechnology organizations, with deep expertise spanning innate and adaptive immunity, translational biology, and therapeutic area strategy.
Previously, Jarrat has held senior scientific and research leadership roles at CSL, Dragonfly Therapeutics, Seeker Biologics, and Johnson & Johnson. He currently serves as Research Therapeutic Area Lead for Immunology, Transplant, and Vaccines at CSL, where he is responsible for setting scientific strategy and advancing research programs across multiple immune-mediated disease areas.
Before joining CSL, Jarrat was Vice President of Immunology and Translation at Dragonfly Therapeutics, where he led immunology and translational biology efforts supporting the advancement of novel immunotherapeutic platforms. He also served as Vice President and Head of Biology at Seeker Biologics, overseeing biology strategy and execution across early-stage discovery programs.
Earlier in his career, Jarrat spent nearly two decades at Johnson & Johnson and the Janssen Pharmaceutical Companies, where he progressed through roles of increasing responsibility including Senior Director of Immunology Scientific Innovation, Director of Lupus Biomarkers, Associate Scientific Director, and Principal Scientist. During this time, he led discovery and biomarker programs in immunology and autoimmune diseases and contributed to the advancement of multiple research-stage and clinical programs.
Throughout his career, Jarrat has been recognized for his ability to translate deep biological insight into therapeutic strategy, advise on immunology-driven investment and development decisions, and support the advancement of innovative programs from discovery through early clinical development.
He holds a Ph.D. in Microbiology from the University of Georgia and a B.S. in Biology from Valdosta State University.